CGC — Canopy Growth Corporation

Canopy Growth Corporation (CGC) Q1 Fiscal 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $72 million, a 19% increase year-over-year.
  • Cannabis Segment: $57 million, up 24% year-over-year.
    • Canada Medical: $22 million, up 13%.
    • Canada Adult-Use: $35 million, up 43%.
    • International: $10 million, up 4%, with Germany showing triple-digit growth.
  • Storz & Bickel Segment: $15 million, down 25% year-over-year.
• Adjusted EBITDA Loss: $8 million, compared to a loss of $5 million in the prior year.
• Gross Margin: 24%, down from the previous year, primarily due to increased production costs and lower sales in high-margin markets.
• Free Cash Flow: Outflow of $12 million, improved from $56 million in the same period last year.
• Cash and Short-term Investments: $144 million; debt balance of $295 million.

2. Strategic Updates and Business Highlights

• Cost Reduction Initiatives: Achieved $17 million in annualized savings, nearing the $20 million target.
• New Product Launches: Storz & Bickel is preparing to launch a new device to enhance consumer appeal.
• Market Expansion: Appointed Miles Worne as Managing Director of European Markets to strengthen commercial strategy and supply consistency.
• Operational Improvements: Focus on enhancing supply chain efficiency and inventory management, particularly in the European market.

3. Forward Guidance and Outlook

• Revenue Growth Expectations: Anticipate continued growth in Canada Medical and adult-use segments, with sustained performance expected throughout fiscal 2026.
• Gross Margin Improvement: Aiming for margins in the low to mid-30% range by the end of the fiscal year through efficiency improvements and strategic pricing.
• Free Cash Flow: Expect significant improvement driven by reduced cash interest costs and better working capital management.

4. Challenges and Points of Concern

• Gross Margin Pressure: Continued decline in gross margins due to higher production costs and lower sales in key markets like Poland and Australia.
• Storz & Bickel Performance: Soft revenue performance attributed to weaker consumer demand and macroeconomic challenges, particularly in the U.S.
• Regulatory Challenges: Issues in Poland due to regulatory changes affecting online prescriptions and supply chain disruptions.

5. Notable Q&A Insights

• Gross Margin Drivers: Management indicated that improvements in gross margins are expected from production efficiencies and prioritizing supply to profitable markets.
• Poland Market Challenges: Luc Mongeau highlighted the need for better internal processes to improve performance in Poland, indicating a focus on fundamentals.
• U.S. Market Outlook: While no specifics on rescheduling were provided, there is optimism about demand and infrastructure development in select U.S. geographies, positioning Canopy for future opportunities.

Overall, Canopy Growth demonstrated strong revenue growth in its cannabis segments while facing challenges in gross margins and the Storz & Bickel business. The company is focused on cost efficiency and strategic market positioning to drive future growth.